C12N 2799/025
Where the vector is derived from a parvovirus
Official title: where the vector is derived from a parvovirus
C12N2799/025 (Where the vector is derived from a parvovirus) appears on 163 US grants and 259 published applications in this corpus.
Search patents in C12N- Granted patents
- 163
- Published applications
- 259
- Assignees
- 137
- Inventors
- 414
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 5 | 0 |
| 2000 | 3 | 0 |
| 2001 | 3 | 2 |
| 2002 | 3 | 11 |
| 2003 | 4 | 8 |
| 2004 | 1 | 10 |
| 2005 | 2 | 8 |
| 2006 | 3 | 8 |
| 2007 | 3 | 5 |
| 2008 | 4 | 17 |
| 2009 | 1 | 11 |
| 2010 | 5 | 15 |
| 2011 | 4 | 16 |
| 2012 | 8 | 21 |
| 2013 | 10 | 19 |
| 2014 | 10 | 14 |
| 2015 | 11 | 12 |
| 2016 | 17 | 15 |
| 2017 | 8 | 19 |
| 2018 | 12 | 8 |
| 2019 | 6 | 10 |
| 2020 | 9 | 9 |
| 2021 | 7 | 7 |
| 2022 | 3 | 3 |
| 2023 | 7 | 7 |
| 2024 | 6 | 2 |
| 2025 | 3 | 1 |
| 2026 | 4 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Gene-therapy vectors for treating cardiomyopathy29 Sep 2026US 12,747,453 B2
- Gene-therapy vectors for treating cardiomyopathy22 Sep 2026US 12,742,181 B2
- Immunomodulating gene therapy26 May 2026US 12,636,302 B2Duke University
- HLA class II deficient cells, HLA class I deficient cells capable of expressing HLA class II proteins, and uses thereof26 May 2026US 12,636,354 B2University of Washington through its Center for Commercialization
- Liver-specific nucleic acid regulatory elements and methods and use thereof9 Sep 2025US 12,409,236 B2Life Sciences Research Partners VZW
- Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof3 Sep 2026US 2026/0256896 A1University of Washington through its Center for Commercialization
- Satiation peptide administration27 Mar 2025US 2025/0099546 A1University of Florida Research Foundation, Inc.
- Adeno-associated virus capsid proteins26 Sep 2024US 2024/0317813 A1Biomarin Pharmaceutical Inc.
- Gene-therapy vectors for treating cardiomyopathy18 Jan 2024US 2024/0018548 A1
- Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders16 Nov 2023US 2023/0364200 A1Genzyme Corporation
Most cited
By later US patents
- Humanized green fluorescent protein genes and methods264US 5,874,304 AUniversity of Florida Research Foundation, Inc. · 1999
- Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme144US 5,962,313 AAvigen, Inc. · 1999
- Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same124US 6,759,237 B1The Trustees of the University of Pennsylvania · 2004
- Adeno-associated virus vectors for expression of factor VIII by target cells112US 6,200,560 B1Avigen, Inc. · 2001
- Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same82US 7,105,345 B2University of Pennsylvania · 2006